Fig.1

NRF2 KD increases the sensitivity of adherent, suspending and 3D cells to GPX4 inhibitors. A IHC scores of NRF2 in primary tumor and metastasis tumors from 51 patients. Primary tumor IHC scores mean ± SD = 1.82 ± 0.76; Metastasis tumor IHC scores mean ± SD = 2.22 ± 0.63). B Cell culture in suspension for 8 h, 1 day, 3 days and 5 days the protein level of NRF2, KEAP1,p62, HO-1 and GPX4 in HM and OVCA429 cells was measured by immune blot. C Quantitative real-time PCR was performed to assess mRNA level of NFE2L2 in HM and OVCA429 cells after suspension growth for 1 day, 3 days and 5 days. D Gene knockdown confirmation after transfected with shRNA targeting NRF2 the NFE2L2 mRNA measured by Quantitative real-time PCR. E HM and OVCA429 cells with or without NFE2L2 knockdown were treated by GPX4 inhibitors for 48 h the cell viability was measured by CCK8 assay. F The inhibitory effect of GPX4 inhibitors on spheroid formation of HM and OVCA429 cells transfected with shNC and shNRF2 was evaluated. G Calcein AM/PI staining was used to assess the cell deaths on 3D spheroid formation of HM and OVCA429 after treatment of GPX4 inhibitor and knockdown of NRF2. Each experiment was performed in triplicate. Statistical significance was represented as *p < 0.05, ** p < 0.01 and *** p < 0.001 compared to the control group